These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22929312)

  • 1. Rapid screening of ASXL1, IDH1, IDH2, and c-CBL mutations in de novo acute myeloid leukemia by high-resolution melting.
    Ibáñez M; Such E; Cervera J; Luna I; Gómez-Seguí I; López-Pavía M; Dolz S; Barragán E; Fuster O; Llop M; Rodríguez-Veiga R; Avaria A; Oltra S; Senent ML; Moscardó F; Montesinos P; Martínez-Cuadrón D; Martín G; Sanz MA
    J Mol Diagn; 2012 Nov; 14(6):594-601. PubMed ID: 22929312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.
    Martínez-Avilés L; Besses C; Álvarez-Larrán A; Torres E; Serrano S; Bellosillo B
    Ann Hematol; 2012 Apr; 91(4):533-41. PubMed ID: 21904853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
    Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
    Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation.
    Yamaguchi S; Iwanaga E; Tokunaga K; Nanri T; Shimomura T; Suzushima H; Mitsuya H; Asou N
    Eur J Haematol; 2014 Jun; 92(6):471-7. PubMed ID: 24443894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
    Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.
    Nomdedéu J; Hoyos M; Carricondo M; Esteve J; Bussaglia E; Estivill C; Ribera JM; Duarte R; Salamero O; Gallardo D; Pedro C; Aventin A; Brunet S; Sierra J
    Leuk Res; 2012 Aug; 36(8):990-7. PubMed ID: 22520341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
    Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
    Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
    Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
    Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation.
    Bill M; Jentzsch M; Bischof L; Kohlschmidt J; Grimm J; Schmalbrock LK; Backhaus D; Brauer D; Goldmann K; Franke GN; Vucinic V; Niederwieser D; Mims AS; Platzbecker U; Eisfeld AK; Schwind S
    Blood Adv; 2023 Feb; 7(3):436-444. PubMed ID: 35381077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mutation of isocitrate dehydrogenase 2 (IDH2) gene in Chinese AML patients and its clinical significance].
    Shang Z; Wang D; Xiao M; Wang J; Li TJ; Zhao YC; Li CR; Zhou JF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):607-12. PubMed ID: 23815907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    Ann Hematol; 2012 Apr; 91(4):519-25. PubMed ID: 21997850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
    Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
    Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.
    DiNardo CD; Ravandi F; Agresta S; Konopleva M; Takahashi K; Kadia T; Routbort M; Patel KP; Mark Brandt ; Pierce S; Garcia-Manero G; Cortes J; Kantarjian H
    Am J Hematol; 2015 Aug; 90(8):732-6. PubMed ID: 26016821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutations in acute myeloid leukemia.
    Rakheja D; Konoplev S; Medeiros LJ; Chen W
    Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.